Cenos Therapeutics is pioneering the future of neurological health through innovative RNA therapeutics. The company’s proprietary BBB-crossing conjugate RNA platform enables deep brain delivery via subcutaneous dosing, offering a safer and more convenient alternative to invasive intrathecal methods. Cenos focuses on high-value orphan diseases like Creutzfeldt-Jakob (CJD) and Tauopathies while partnering to address larger indications such as Alzheimer’s and Parkinson’s disease. Early data demonstrates significant mRNA and protein knockdown in preclinical models, with the lead program showing promise for CJD. With a robust IP portfolio extending to 2043 and a seasoned team of experts in RNA delivery, Cenos is raising seed funding to advance its programs through non-human primate (NHP) validation and candidate selection.